Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Sonelokimab · ALX-0761, M-1095

Bispecific antibody · developed by MoonLake Immunotherapeutics

Phase 3 Most advanced trial
MLTX Developer
2 Registered trials

What is Sonelokimab?

Sonelokimab (ALX-0761, M-1095) is an antibody studied in psoriatic arthritis and hidradenitis suppurativa.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ALX-0761, M-1095
Drug type
Bispecific antibody
Therapy area
Dermatology
Developer
MoonLake Immunotherapeutics AG (MLTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
LEN0OCZ4SH

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06641089 Phase 3 Arthritis, Psoriatic Active not recruiting MLTX
NCT05322473 Phase 2 Hidradenitis Suppurativa Completed MLTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Arthritis, PsoriaticHidradenitis Suppurativa

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the MLTX page.

Follow MLTX, the company behind Sonelokimab

See MLTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MLTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.